Handbook of Clinical medicine
KEYWORDS: patient, disease, patients, history, pain, heart, symptoms, ask, time, treatment, risk, examination, aortic, iinnddbb, pulse

via Rare and Imported Pathogens Laboratory (RIPL): www. gov.uk/government/collections/rare-and-imported-pathogens-laboratory-ripl __OOHHCCMM__1100ee..iinnddbb 442222 0022//0055//22001177 1199::0077 sesaesid suoitcefnI Leishmaniasis 423 Caused by protozoan parasites of Leishmania12 species, transmitted by infected female phlebotomine sandfl ies. 556 million at risk. Risk factors: poverty, malnutrition, displace- ment, deforestation, dam building/irrigation. Presentation: • Cutaneous, most common form, ulceration (fi g 9.56, p440). Fig 9.32 Mucocutane- • Mucocutaneous (fi g 9.32): leads to tissue destruction of ous leishmaniasis. nose, mouth, throat. 90% occurs in Bolivia, Brazil, Peru. Reproduced with permis- • Visceral leishmaniasis (VL, kala-azar, ‘black sickness’) (fi g sion from World Health 9.33): fever, weight loss, hepatosplenomegaly, anaemia. Organization. © World >95% mortality without treatment. Endemic in Indian sub- Health Organization. http:// continent, East Africa. 90% of new cases occur in Bangla- www.who.int/leishmaniasis/mu- desh, Brazil, Ethiopia, India, South Sudan, Sudan. 300 000 cocutaneous_leishmaniasis/en/ cases/yr, 20 000 deaths/yr. Post kala-azar is a complication of Leishmania donovani = a hypopigmented macular/nodular rash ( leprosy), 6 months–1yr after apparent cure, can heal but is a reservoir for parasites and maintains transmission. Diagnosis: Clinical. Microscopy of tissue samples (skin, bone marrow) for parasite. Antibody detection in VL (indirect fl uores- cence, ELISA, western blot, direct agglutination test, or immuno- chromatographic test)
